Use of Glucagon‐Like Peptide‐1 Receptor Agonists in Danish Adolescents and Young Adults 2018–2025
Authors' conclusion
Findings demonstrate rapid uptake of GLP-1RAs in youth
Study context
- Population
- All 12- to 24-year-olds in Denmark who filled a GLP-1RA prescription, January 2018–December 2025; nationwide prescription, hospital and laboratory registries
- Exposure
- 18-24 years vs 12-17 years
- Outcome
- Trends in GLP-1RA use (incidence of use)
- Follow-up
- 2018-2025
Methodological detailsnationwide, registry-based
- Nationwide
- Registry-based
Main finding
As reported in the abstract
Incidence of GLP-1RA use (new users per 100,000) · 2018 to 2025
18-24 years
from 13 to 686 per 100,000
12-17 years
from 1.7 to 72 per 100,000
- New users per 100,000 by 2025, driven by semaglutide for weight management
- 418 per 100,000
Observational data: associations, not effects.
Further findings
User characteristics
- Psychiatric comorbidity, particularly emotional and neurodevelopmental disorders
- 33%
- Most users were female, few had diabetes
Prescribing patterns · 2025
- New treatments initiated in general practice
- 78%
Treatment persistence · 1 year
- Covered by a prescription after 1 year
- 38%
Original publication
Use of Glucagon‐Like Peptide‐1 Receptor Agonists in Danish Adolescents and Young Adults 2018–2025. Obesity (Silver Spring). Published 7 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →